Results were featured as late-breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies ...

A year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur from accidental exposure to certain foods, the companies ...

Xolair is the only U.S. FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies – Genentech, a member of the Roche Group (SIX: RO, ROG ...

Approximately 45,000 patients have begun using omalizumab for food allergy in the year since its approval by the FDA, Ahmar ...

Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide further evidence supporting the role of Xolair ...

Results were featured as late-breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies ...

Xolair, a drug developed 15 years ago by Roche and Novartis, received a breakthrough designation from the US regulator in a new food allergy indication. The Food and Drug Administration (FDA ...

Genentech said Sunday that in the first head-to-head trial comparing Xolair to oral immunotherapy, the study met its primary endpoint showing 36% of food allergy patients treated with Xolair ...

“These latest data provide additional evidence demonstrating the importance of Xolair as a treatment option for the food allergy community,” said Levi Garraway, M.D., Ph.D., chief medical ...